Ruxolitinib: gaining more than intended

Research output: Contribution to journalComment/debatepeer-review

4 Downloads (Pure)

Abstract

In this issue of Blood, Mollé et al demonstrate that on-target effects of ruxolitinib, a JAK1/2 inhibitor, reduce JAK2-mediated phosphorylation of STAT3 in the arcuate nucleus of the murine hypothalamus in response to feeding or exogenous leptin, proposing a novel mechanism for the weight gain observed with this drug.
Original languageEnglish
Pages (from-to)983-984
Number of pages2
JournalBlood
Volume135
Issue number13
DOIs
Publication statusPublished - 26 Mar 2020

Fingerprint

Dive into the research topics of 'Ruxolitinib: gaining more than intended'. Together they form a unique fingerprint.

Cite this